| Publications | PubMed=1747867; DOI=10.1016/0165-4608(91)90359-3
Karnes P.S., Tran T.N., Cui M.-Y., Bogenmann E., Shimada H., Ying K.-L.
Establishment of a rhabdoid tumor cell line with a specific chromosomal abnormality, 46,XY,t(11;22)(p15.5;q11.23).
Cancer Genet. Cytogenet. 56:31-38(1991) PubMed=8385567; DOI=10.1002/1097-0142(19930501)71:9<2862::AID-CNCR2820710930>3.0.CO;2-D
Ota S., Crabbe D.C.G., Tran T.N., Triche T.J., Shimada H.
Malignant rhabdoid tumor. A study with two established cell lines.
Cancer 71:2862-2872(1993) PubMed=8818656; DOI=10.1002/(SICI)1098-2264(199606)16:2<94::AID-GCC3>3.0.CO;2-Y
Biegel J.A., Allen C.S., Kawasaki K., Shimizu N., Budarf M.L., Bell C.J.
Narrowing the critical region for a rhabdoid tumor locus in 22q11.
Genes Chromosomes Cancer 16:94-105(1996) PubMed=9559292; DOI=10.1097/00019606-199712000-00004
Suzuki A., Ohta S., Shimada M.
Gene expression of malignant rhabdoid tumor cell lines by reverse transcriptase-polymerase chain reaction.
Diagn. Mol. Pathol. 6:326-332(1997) PubMed=9671307; DOI=10.1038/28212
Versteege I., Sevenet N., Lange J., Rousseau-Merck M.-F., Ambros P.F., Handgretinger R., Aurias A., Delattre O.
Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.
Nature 394:203-206(1998) PubMed=9920784; DOI=10.1006/bbrc.1998.9968
Mori T., Fukuda Y., Kuroda H., Matsumura T., Ota S., Sugimoto T., Nakamura Y., Inazawa J.
Cloning and characterization of a novel Rab-family gene, Rab36, within the region at 22q11.2 that is homozygously deleted in malignant rhabdoid tumors.
Biochem. Biophys. Res. Commun. 254:594-600(1999) PubMed=10397258
Rousseau-Merck M.-F., Versteege I., Legrand I., Couturier J., Mairal A., Delattre O., Aurias A.
hSNF5/INI1 inactivation is mainly associated with homozygous deletions and mitotic recombinations in rhabdoid tumors.
Cancer Res. 59:3152-3156(1999) PubMed=10602515; DOI=10.1038/sj.onc.1203168
DeCristofaro M.F., Betz B.L., Wang W.-D., Weissman B.E.
Alteration of hSNF5/INI1/BAF47 detected in rhabdoid cell lines and primary rhabdomyosarcomas but not Wilms' tumors.
Oncogene 18:7559-7565(1999) PubMed=11557780; DOI=10.1038/modpathol.3880401
Itakura E., Tamiya S., Morita K., Shiratsuchi H., Kinoshita Y., Oshiro Y., Oda Y., Ohta S., Furue M., Tsuneyoshi M.
Subcellular distribution of cytokeratin and vimentin in malignant rhabdoid tumor: three-dimensional imaging with confocal laser scanning microscopy and double immunofluorescence.
Mod. Pathol. 14:854-861(2001) PubMed=11921280; DOI=10.1002/gcc.10052
Uno K., Takita J., Yokomori K., Tanaka Y., Ohta S., Shimada H., Gilles F.H., Sugita K., Abe S., Sako M., Hashizume K., Hayashi Y.
Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors.
Genes Chromosomes Cancer 34:33-41(2002) PubMed=12210830; DOI=10.1002/jnr.10330
Yoshida S., Narita T., Taga T., Ohta S., Takeuchi Y.
Malignant rhabdoid tumor shows incomplete neural characteristics as revealed by expression of SNARE complex.
J. Neurosci. Res. 69:642-652(2002) PubMed=14662021; DOI=10.1111/j.1349-7006.2003.tb01401.x; PMCID=PMC11160295
Kato H., Ohta S., Koshida S., Narita T., Taga T., Takeuchi Y., Sugita K.
Expression of pericyte, mesangium and muscle markers in malignant rhabdoid tumor cell lines: differentiation-induction using 5-azacytidine.
Cancer Sci. 94:1059-1065(2003) PubMed=16557275; DOI=10.1038/modpathol.3800599
Izumi T., Oda Y., Hasegawa T., Nakanishi Y., Iwasaki H., Sonobe H., Goto H., Kusakabe H., Takahira T., Kobayashi C., Kawaguchi K.-i., Saito T., Yamamoto H., Tamiya S., Iwamoto Y., Tsuneyoshi M.
Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Mod. Pathol. 19:820-831(2006) PubMed=24418192; DOI=10.1111/cas.12352; PMCID=PMC4317948
Takita J., Chen Y.-Y., Kato M., Ohki K., Sato Y., Ohta S., Sugita K., Nishimura R., Hoshino N., Seki M., Sanada M., Oka A., Hayashi Y., Ogawa S.
Genome-wide approach to identify second gene targets for malignant rhabdoid tumors using high-density oligonucleotide microarrays.
Cancer Sci. 105:258-264(2014) PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019) |
|---|
